Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311
NEW HAVEN, Conn. — September 29, 202 Invivyd announced topline results from the Phase 3 LIBERTY study evaluating VYD2311,...
mRNA Vaccine
Advertisement
Kyowa Kirin Reaches U.S. Agreement to Lower Medicine Costs
TOKYO, Japan and PRINCETON, New Jersey, Aug. 31/Sept. 1, 2026 Kyowa Kirin Co., Ltd. announced a voluntary agreement with...
GSK Advances mRNA Flu Vaccine to Phase III After Data
LONDON, UK, Sept. 1, 2026 GSK announced that it will advance its investigational mRNA seasonal influenza vaccine candidate into...
Moderna Wins FDA Approval for 2026-27 COVID Vaccines
Cambridge, Massachusetts, August 27, 2026 Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved supplemental...
Pfizer and BioNTech Win FDA Approval for XFG COVID-19 Vaccine
NEW YORK, NY and MAINZ, Germany – August 27, 2026 Pfizer Inc. and BioNTech SE announced that the U.S....
Advertisements
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine
CAMBRIDGE, Mass., Aug. 5, 2026 Moderna, Inc. has received U.S. Food and Drug Administration (FDA) approval for mFLUSIVA® (mRNA-1010),...
Pfizer and BioNTech Win EU Approval for XFG COVID-19 Vaccine
NEW YORK and MAINZ, Germany, July 29, 2026 Pfizer Inc. and BioNTech SE announced that the European Commission (EC)...
Vaxart Reports Positive 12-Month Phase 2b Safety Data
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Vaxart, Inc. has announced positive topline 12-month safety results from the approximately...
Moderna Publishes Positive Phase 3 Clinical Data for mRNA-1010 Seasonal Influenza Vaccine in New England Journal of Medicine
CAMBRIDGE, Mass., May 6, 2026 Moderna announced the publication of pivotal Phase 3 clinical safety and efficacy data for...
Pfizer and BioNTech Report Strong Data for LP.8.1-Adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)...
Advertisement
